Rejuvenate hip recall hits Stryker's Q2 profits

July 19, 2013 by Brad Perriello

Stryker Corp.'s 2nd-quarter profits plunge nearly 35% on costs related to the recall of its Rejuvenate hip implant, as it misses Wall Street's earnings expectations and lowers its 2013 outlook.

Rejuvenate, ABG II hip recalls hit Stryker's Q2 profits

Stryker (NYSE:SYK) said an unexpected, $170 million hit related to its recalled Rejuvenate hip implant pushed its 2nd-quarter profits down nearly 35% and lowered its earnings outlook for the rest of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.